The PROpel Phase III trial showed that AstraZeneca (LSE: AZN) and Merck & Co’s (NYSE: MRK) Lynparza (olaparib) alongside Zytiga (abiraterone) significantly improved radiographic progression-free survival (rPFS) versus abiraterone alone as a first-line treatment in metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations.
These results, showing the combination reduced the risk of disease progression or death by 34% versus Zytiga alone, are now published in the New England Journal of Medicine (NEJM) Evidence.
Zytiga is manufactured by the Johnson & Johnson (NYSE: JNJ) unit Janssen and was first introduced to the market in 2011.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze